載入...
New frontiers in the medical management of gastrointestinal stromal tumours
The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardina...
Na minha lista:
| 發表在: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535752/ https://ncbi.nlm.nih.gov/pubmed/31205499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919841946 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|